Dynavax Technologies reported $221.58M in Debt for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Debt Change
Adma Biologics ADMA:US USD 141.37M 1.56M
Agenus AGEN:US USD 13.16M 299K
Amgen AMGN:US USD 38.94B 241M
AstraZeneca AZN:LN USD 29.23B 67M
Astrazeneca AZN:US USD 29.23B 67M
Biogen BIIB:US USD 6.28B 1.8M
Biomarin Pharmaceutical BMRN:US USD 1.09B 3.46M
Bristol Myers Squibb BMY:US USD 39.32B 222M
Dynavax Technologies DVAX:US USD 221.58M 275K
Glaxosmithkline GSK:US GBP 20.99B 1.13B
Neurocrine Biosciences NBIX:US USD 169.4M 200K
Novartis NOVN:VX USD 27.91B 530M
Regeneron Pharmaceuticals REGN:US USD 2.7B 300K
Roche Holding ROG:VX 25.35B 2.4B
Sarepta Therapeutics SRPT:US USD 1.54B 1.52M
Tg Therapeutics TGTX:US USD 71.13M 1.1M
Vertex Pharmaceuticals VRTX:US USD 471.6M 29.3M